US FDA Approves Daraxonrasib as Breakthrough Treatment for Pancreatic Cancer
Source Summary
The US drug agency has approved daraxonrasib, a treatment that experts describe as a game changer for pancreatic cancer, one of the world's deadliest cancers.
Why it matters
Pancreatic cancer is among the world's deadliest cancers, and expert recognition of this drug as a game changer indicates potential to improve survival outcomes for patients with limited treatment options.
